MRI With C13 Pilot Study Prostate Cancer
NCT02450201 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 5
Last updated 2018-10-23
Summary
This is a pilot clinical study of hyperpolarized pyruvate (13C) injection that includes the acquisition of magnetic resonance (MR) data and will be performed in men with localized prostate cancer. Part 1: Five patients will be evaluated for reproducibility of 13C HP MR imaging measurements obtained 2-3 weeks apart with no interim treatment. Part 2: Five patients will be evaluated for the change in 13C HP MR imaging measurements after 2 months of ADT.
13C HP MR data will be acquired in two parts of the study (which can occur simultaneously): Part 1: Patients will undergo imaging at baseline and will be repeated two to three weeks later (with no intervention in the interim) to evaluate reproducibility.
Part 2: Patients will undergo imaging at baseline, initiate androgen deprivation therapy, and undergo repeat imaging two months after initiation of ADT to evaluate the ability of the imaging to reflect a metabolic response to treatment.
The change in pyruvate/lactate ratio and lactate levels will be measured and compared to baseline at these timepoints.
Conditions
Interventions
- DRUG
-
Pyruvate
Sponsors & Collaborators
-
University of California, San Francisco
lead OTHER
Principal Investigators
-
Rahul Aggarwal, MD · University of California, San Francisco
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- DIAGNOSTIC
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-10-12
- Primary Completion
- 2017-01-17
- Completion
- 2017-01-17
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer
NCT02526368 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer
NCT04346225 ·Status: RECRUITING ·Phase: PHASE2
-
Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone
NCT06384222 ·Status: RECRUITING ·Phase: PHASE2
-
Utility of Hyperpolarized 13C-pyruvate Metabolic Magnetic Resonance Imaging
NCT04698564 ·Status: RECRUITING ·Phase: PHASE2
-
MRI Before Biopsy in Diagnosing Patients With Prostate Cancer
NCT02131207 ·Status: TERMINATED
-
Correlation of Imaging Findings With Clinical Findings and Patient Outcomes in Prostate Cancer
NCT03122470 ·Status: WITHDRAWN ·Phase: NA
-
Magnetic Resonance (MR) Imaging With Hyperpolarized Pyruvate (HP) (13C) in Castration-Resistant Prostate Cancer
NCT02911467 ·Status: TERMINATED ·Phase: PHASE1
-
PSMA-PET/MRI Low- and Intermediate-Risk Prostate Cancer
NCT04243941 ·Status: WITHDRAWN ·Phase: PHASE2
-
Incorporating MR Imaging Into Prostate Radiotherapy Treatment Planning
NCT02470910 ·Status: COMPLETED ·Phase: NA
-
Magnetic Resonance Imaging in Detecting Cancer Progression in Patients With Early Stage Prostate Cancer Undergoing Active Surveillance
NCT00796874 ·Status: WITHDRAWN ·Phase: NA
-
Using Magnetic Resonance Imaging (MRI) to Guide Differential-Dose Prostate Brachytherapy
NCT01913197 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer
NCT05851365 ·Status: ACTIVE_NOT_RECRUITING ·Phase: EARLY_PHASE1
-
Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) Injection
NCT02647983 ·Status: WITHDRAWN ·Phase: PHASE1
-
Positron Emission Tomography and Magnetic Resonance Imaging for Prostate Cancer
NCT00924313 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
MRI Guided Prostate Cancer Focal Laser Ablation
NCT03634579 ·Status: TERMINATED ·Phase: NA
-
MRI in Diagnosing Prostate Cancer
NCT01292291 ·Status: UNKNOWN ·Phase: NA
-
Prostate Imaging Using MRI +/- Contrast Enhancement
NCT04571840 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Characterize Tumor Hypoxia by Magnetic Resonance Imaging
NCT03987568 ·Status: WITHDRAWN ·Phase: NA
-
Hyperpolarized Carbon-13 Imaging of Metastatic Prostate Cancer
NCT02844647 ·Status: TERMINATED ·Phase: PHASE1
-
Magnetic Resonance Imaging to Locate and Characterize Prostate Cancer
NCT00082147 ·Status: COMPLETED ·Phase: NA
-
Evaluation of MRI for Prostate Cancer
NCT00930748 ·Status: TERMINATED
-
Contrast Enhanced MRI of the Prostate
NCT02245282 ·Status: COMPLETED
-
Phase I Study of Intensity Modulated Radiation Therapy for Prostate Cancer
NCT00124917 ·Status: TERMINATED ·Phase: PHASE1
-
Multi-parametric Magnetic Resonance Imaging for Prostate Cancer Patients
NCT03180398 ·Status: TERMINATED ·Phase: NA
-
The Value of Dual-parametric Magnetic Resonance Combined With Regional Saturation Biopsy in Patients With Suspected Prostate Cancer
NCT06824259 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA